Severe BCG immune reconstitution inflammatory syndrome lymphadenitis successfully managed with pre-antiretroviral counseling and a non-surgical approach: a case report.
ART
BCG
HIV
IRIS
Lymphadenitis
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
27 Apr 2024
27 Apr 2024
Historique:
received:
23
02
2024
accepted:
09
04
2024
medline:
28
4
2024
pubmed:
28
4
2024
entrez:
27
4
2024
Statut:
epublish
Résumé
Bacillus Calmette-Guérin (BCG) reactions are the most common cause of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive infants who initiate antiretroviral therapy (ART). There is limited evidence regarding the incidence of BCG-IRIS; however, reports from outpatient cohorts have estimated that 6-9% of infants who initiated ART developed some form of BCG-IRIS within the first 6 months. Various treatment approaches for infants with BCG-IRIS have been reported, but there is currently no widely accepted standard-of-care. A 5-month-old male HIV-exposed infant BCG vaccinated at birth was admitted for refractory oral candidiasis, moderate anemia, and moderate acute malnutrition. He had a HIV DNA-PCR collected at one month of age, but the family never received the results. He was diagnosed with HIV during hospitalization with a point-of-care nucleic acid test and had severe immune suppression with a CD4 of 955 cells/µL (15%) with clinical stage III disease. During pre-ART counseling, the mother was educated on the signs and symptoms of BCG-IRIS and the importance of seeking follow-up care and remaining adherent to ART if symptoms arose. Three weeks after ART initiation, he was readmitted with intermittent subjective fevers, right axillary lymphadenopathy, and an ulcerated papule over the right deltoid region. He was subsequently discharged home with a diagnosis of local BCG-IRIS lymphadenitis. At six weeks post-ART initiation, he returned with suppurative lymphadenitis of the right axillary region that had completely eviscerated through the skin without signs of disseminated BCG disease. He was then started on an outpatient regimen of topical isoniazid, silver nitrate, and oral prednisolone. Throughout this time, the mother maintained good ART adherence despite this complication. After 2.5 months of ART and one month of specific treatment for the lymphadenitis, he had marked mass reduction, improved adenopathy, increased CD4 count, correction of anemia, and resolution of his acute malnutrition. He completely recovered and was symptom free two months after initial treatment without surgical intervention. This case details the successful management of severe suppurative BCG-IRIS with a non-surgical approach and underlines the importance of pre-ART counseling on BCG-IRIS for caregivers, particularly for infants who initiate ART with advanced HIV.
Sections du résumé
BACKGROUND
BACKGROUND
Bacillus Calmette-Guérin (BCG) reactions are the most common cause of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive infants who initiate antiretroviral therapy (ART). There is limited evidence regarding the incidence of BCG-IRIS; however, reports from outpatient cohorts have estimated that 6-9% of infants who initiated ART developed some form of BCG-IRIS within the first 6 months. Various treatment approaches for infants with BCG-IRIS have been reported, but there is currently no widely accepted standard-of-care.
CASE PRESENTATION
METHODS
A 5-month-old male HIV-exposed infant BCG vaccinated at birth was admitted for refractory oral candidiasis, moderate anemia, and moderate acute malnutrition. He had a HIV DNA-PCR collected at one month of age, but the family never received the results. He was diagnosed with HIV during hospitalization with a point-of-care nucleic acid test and had severe immune suppression with a CD4 of 955 cells/µL (15%) with clinical stage III disease. During pre-ART counseling, the mother was educated on the signs and symptoms of BCG-IRIS and the importance of seeking follow-up care and remaining adherent to ART if symptoms arose. Three weeks after ART initiation, he was readmitted with intermittent subjective fevers, right axillary lymphadenopathy, and an ulcerated papule over the right deltoid region. He was subsequently discharged home with a diagnosis of local BCG-IRIS lymphadenitis. At six weeks post-ART initiation, he returned with suppurative lymphadenitis of the right axillary region that had completely eviscerated through the skin without signs of disseminated BCG disease. He was then started on an outpatient regimen of topical isoniazid, silver nitrate, and oral prednisolone. Throughout this time, the mother maintained good ART adherence despite this complication. After 2.5 months of ART and one month of specific treatment for the lymphadenitis, he had marked mass reduction, improved adenopathy, increased CD4 count, correction of anemia, and resolution of his acute malnutrition. He completely recovered and was symptom free two months after initial treatment without surgical intervention.
CONCLUSIONS
CONCLUSIONS
This case details the successful management of severe suppurative BCG-IRIS with a non-surgical approach and underlines the importance of pre-ART counseling on BCG-IRIS for caregivers, particularly for infants who initiate ART with advanced HIV.
Identifiants
pubmed: 38678293
doi: 10.1186/s12981-024-00614-7
pii: 10.1186/s12981-024-00614-7
doi:
Substances chimiques
BCG Vaccine
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Informations de copyright
© 2024. The Author(s).
Références
Joint United Nations Programme on HIV/AIDS (UNAIDS). Progress towards the Start Free, stay free, AIDS Free targets: 2020 report. Switzerland: Geneva; 2020.
Alexander A, Rode H. Adverse reactions to the Bacillus Calmette-Guerin vaccine in HIV-positive infants. J Pediatr Surg. 2007;42(3):549–52.
doi: 10.1016/j.jpedsurg.2006.10.059
pubmed: 17336197
World Health Organization. BCG vaccines: WHO position paper – February 2018 – vaccines BCG. Wkly Epidemiol Rec. 2018;93(08):73–96.
Tappuni AR. Immune reconstitution inflammatory syndrome. Adv Dent Res. 2011;23(1):90–6.
doi: 10.1177/0022034511399915
pubmed: 21441488
Hesseling AC, et al. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42(4):548–58.
doi: 10.1086/499953
pubmed: 16421800
Rabie H, et al. Early antiretroviral treatment reduces risk of Bacille Calmette-Guerin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011;15(9):1194–200. i.
doi: 10.5588/ijtld.10.0721
pubmed: 21943845
Nuttall JJ, et al. Bacillus Calmette-Guerin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis. 2008;12(6):e99–105.
doi: 10.1016/j.ijid.2008.06.014
pubmed: 18799339
Cotton MF, et al. A prospective study of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children from high prevalence countries. PLoS ONE. 2019;14(7):e0211155.
doi: 10.1371/journal.pone.0211155
pubmed: 31260455
pmcid: 6602181
Liu C, et al. The role of surgical management of BCG vaccine-induced regional suppurative lymphadenitis in children: a 7 years’ experience from one medical center. BMC Infect Dis. 2021;21(1):801.
doi: 10.1186/s12879-021-06531-8
pubmed: 34380453
pmcid: 8359026
Baki A, et al. Therapy of regional lymphadenitis following BCG vaccination. Infection. 1991;19(6):414–6.
doi: 10.1007/BF01726452
pubmed: 1816112
Ritz N, et al. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53(1):316–8.
doi: 10.1128/AAC.01302-08
pubmed: 18955515
Smith K, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009;23(9):1097–107.
doi: 10.1097/QAD.0b013e32832afefc
pubmed: 19417581
Kroidl A, et al. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child. Scand J Infect Dis. 2006;38(8):716–8.
doi: 10.1080/00365540500452473
pubmed: 16857624
Elsidig N, et al. Bacillus Calmette-Guerin vaccine related lymphadenitis in children: management guidelines endorsed by the Saudi Pediatric Infectious Diseases Society (SPIDS). Int J Pediatr Adolesc Med. 2015;2(2):89–95.
doi: 10.1016/j.ijpam.2015.05.003
pubmed: 30805444
pmcid: 6372430
Cuello-Garcia CA, Perez-Gaxiola G, Jimenez C, Gutierrez. Treating BCG-induced disease in children. Cochrane Database Syst Rev. 2013;2013(1):CD008300.
pubmed: 23440826
pmcid: 6532703
Murthy AR, et al. Treatment guidelines and prognosis of immune reconstitution inflammatory syndrome patients: a review. J Int Oral Health. 2015;7(4):92–5.
pubmed: 25954081
pmcid: 4409807
Montelongo-Peralta LZ, et al. Antibacterial activity of combinatorial treatments composed of transition-metal/antibiotics against Mycobacterium tuberculosis. Sci Rep. 2019;9(1):5471.
doi: 10.1038/s41598-019-42049-5
pubmed: 30940878
pmcid: 6445279
Tabaran AF, et al. Silver nanoparticles for the therapy of tuberculosis. Int J Nanomed. 2020;15:2231–58.
doi: 10.2147/IJN.S241183
Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. Lancet Infect Dis. 2015;15(9):1091–9.
doi: 10.1016/S1473-3099(15)00263-7
pubmed: 26277036
Gkentzi D, et al. Incidence, spectrum and outcome of immune reconstitution syndrome in HIV-infected children after initiation of antiretroviral therapy. Pediatr Infect Dis J. 2014;33(9):953–8.
doi: 10.1097/INF.0000000000000331
pubmed: 24618936
Puthanakit T, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2006;25(1):53–8.
doi: 10.1097/01.inf.0000195618.55453.9a
pubmed: 16395104
pmcid: 1924530
Grant PM, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE. 2010;5(7):e11416.
doi: 10.1371/journal.pone.0011416
pubmed: 20617176
pmcid: 2895658
Manabe YC, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46(4):456–62.
doi: 10.1097/QAI.0b013e3181594c8c
pubmed: 18077835
Khumalo PN, et al. The Cascade of Care from Routine Point-of-care HIV Testing at Birth: results from an 18-Months pilot program in Eswatini. J Acquir Immune Defic Syndr. 2020;84(Suppl 1):S22–7.
doi: 10.1097/QAI.0000000000002380
pubmed: 32520911
pmcid: 7302329
Spooner E, et al. Point-of-care HIV testing best practice for early infant diagnosis: an implementation study. BMC Public Health. 2019;19(1):731.
doi: 10.1186/s12889-019-6990-z
pubmed: 31185962
pmcid: 6560857